Journal Article

DZNE-2023-00569

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Higher plasma β‐synuclein indicates early synaptic degeneration in Alzheimer's disease

Oeckl, P. (First author)DZNE* ; Janelidze, S. ; Halbgebauer, S.DZNE* ; Stomrud, E. ; Palmqvist, S. ; Otto, M. ; Hansson, O.

2023
Wiley Hoboken, NJ

This record in other databases:    

Please use a persistent id in citations: doi:10.1002/alz.13103

Abstract: β-Synuclein is an emerging synaptic blood biomarker for Alzheimer's disease (AD) but differences in β-synuclein levels in preclinical AD and its association with amyloid and tau pathology have not yet been studied.We measured plasma β-synuclein levels in cognitively unimpaired individuals with positive Aβ-PET (i.e., preclinical AD, N = 48) or negative Aβ-PET (N = 61), Aβ-positive patients with mild cognitive impairment (MCI, N = 36), and Aβ-positive AD dementia (N = 85). Amyloid (A) and tau (T) pathology were assessed by [18 F]flutemetamol and [18 F]RO948 PET.Plasma β-synuclein levels were higher in preclinical AD and even higher in MCI and AD dementia. Stratification according to amyloid/tau pathology revealed higher β-synuclein in A+ T- and A+ T+ subjects compared with A- T- . Plasma β-synuclein levels were related to tau and Aβ pathology and associated with temporal cortical thinning and cognitive impairment.Our data indicate that plasma β-synuclein might track synaptic dysfunction, even during the preclinical stages of AD.Plasma β-synuclein is already higher in preclinical AD. Plasma β-synuclein is higher in MCI and AD dementia than in preclinical AD. Aβ- and tau-PET SUVRs are associated with plasma β-synuclein levels. Plasma β-synuclein is already higher in tau-PET negative subjects. Plasma β-synuclein is related to temporal cortical atrophy and cognitive impairment.

Keyword(s): Humans (MeSH) ; Alzheimer Disease: pathology (MeSH) ; tau Proteins (MeSH) ; Amyloid beta-Peptides (MeSH) ; beta-Synuclein (MeSH) ; Cognitive Dysfunction: pathology (MeSH) ; Biomarkers (MeSH) ; Amyloid (MeSH) ; Amyloidogenic Proteins (MeSH) ; Positron-Emission Tomography (MeSH) ; amyloid-β PET ; amyloid-β PET ; amyloid-β PET ; blood biomarker ; preclinical Alzheimer's disease ; synaptic degeneration ; tau-PET ; β-Synuclein ; β-Synuclein ; tau Proteins ; Amyloid beta-Peptides ; beta-Synuclein ; Biomarkers ; Amyloid ; Amyloidogenic Proteins ; β-Synuclein

---

Contributing Institute(s):

1. Translational Mass Spectrometry and Biomarker Research (AG Öckl)
2. Clinical Study Center Ulm (Clinical Study Center Ulm)

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Appears in the scientific report 2023

---

Database coverage:
; ; ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DEAL Wiley ; Essential Science Indicators ; IF >= 10 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---